77 related articles for article (PubMed ID: 16331603)
1. A prostate secretory protein94-derived synthetic peptide PCK3145 inhibits VEGF signalling in endothelial cells: implication in tumor angiogenesis.
Lamy S; Ruiz MT; Wisniewski J; Garde S; Rabbani SA; Panchal C; Wu JJ; Annabi B
Int J Cancer; 2006 May; 118(9):2350-8. PubMed ID: 16331603
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of MMP-9 secretion by the anti-metastatic PSP94-derived peptide PCK3145 requires cell surface laminin receptor signaling.
Annabi B; Bouzeghrane M; Currie JC; Dulude H; Daigneault L; Garde S; Rabbani SA; Panchal C; Wu JJ; Béliveau R
Anticancer Drugs; 2006 Apr; 17(4):429-38. PubMed ID: 16550001
[TBL] [Abstract][Full Text] [Related]
3. A PSP94-derived peptide PCK3145 inhibits MMP-9 secretion and triggers CD44 cell surface shedding: implication in tumor metastasis.
Annabi B; Bouzeghrane M; Currie JC; Hawkins R; Dulude H; Daigneault L; Ruiz M; Wisniewski J; Garde S; Rabbani SA; Panchal C; Wu JJ; Béliveau R
Clin Exp Metastasis; 2005; 22(5):429-39. PubMed ID: 16283486
[TBL] [Abstract][Full Text] [Related]
4. A synthetic 15-mer peptide (PCK3145) derived from prostate secretory protein can reduce tumor growth, experimental skeletal metastases, and malignancy-associated hypercalcemia.
Shukeir N; Arakelian A; Chen G; Garde S; Ruiz M; Panchal C; Rabbani SA
Cancer Res; 2004 Aug; 64(15):5370-7. PubMed ID: 15289344
[TBL] [Abstract][Full Text] [Related]
5. Prostate secretory protein of 94 amino acids (PSP-94) and its peptide (PCK3145) as potential therapeutic modalities for prostate cancer.
Shukeir N; Garde S; Wu JJ; Panchal C; Rabbani SA
Anticancer Drugs; 2005 Nov; 16(10):1045-51. PubMed ID: 16222145
[TBL] [Abstract][Full Text] [Related]
6. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
Sun J; Blaskovich MA; Jain RK; Delarue F; Paris D; Brem S; Wotoczek-Obadia M; Lin Q; Coppola D; Choi K; Mullan M; Hamilton AD; Sebti SM
Cancer Res; 2004 May; 64(10):3586-92. PubMed ID: 15150116
[TBL] [Abstract][Full Text] [Related]
7. Safety and tolerability of PCK3145, a synthetic peptide derived from prostate secretory protein 94 (PSP94) in metastatic hormone-refractory prostate cancer.
Hawkins RE; Daigneault L; Cowan R; Griffiths R; Panchal C; Armstrong A; Fenemore J; Irvine A; Sereda K; Dulude H
Clin Prostate Cancer; 2005 Sep; 4(2):91-9. PubMed ID: 16197609
[TBL] [Abstract][Full Text] [Related]
8. Emodin inhibits vascular endothelial growth factor-A-induced angiogenesis by blocking receptor-2 (KDR/Flk-1) phosphorylation.
Kwak HJ; Park MJ; Park CM; Moon SI; Yoo DH; Lee HC; Lee SH; Kim MS; Lee HW; Shin WS; Park IC; Rhee CH; Hong SI
Int J Cancer; 2006 Jun; 118(11):2711-20. PubMed ID: 16388516
[TBL] [Abstract][Full Text] [Related]
9. Contribution of the 37-kDa laminin receptor precursor in the anti-metastatic PSP94-derived peptide PCK3145 cell surface binding.
Annabi B; Currie JC; Bouzeghrane M; Dulude H; Daigneault L; Garde S; Rabbani SA; Panchal C; Wu JJ; Béliveau R
Biochem Biophys Res Commun; 2006 Jul; 346(1):358-66. PubMed ID: 16759641
[TBL] [Abstract][Full Text] [Related]
10. ATL-1, an analogue of aspirin-triggered lipoxin A4, is a potent inhibitor of several steps in angiogenesis induced by vascular endothelial growth factor.
Cezar-de-Mello PF; Vieira AM; Nascimento-Silva V; Villela CG; Barja-Fidalgo C; Fierro IM
Br J Pharmacol; 2008 Mar; 153(5):956-65. PubMed ID: 18193074
[TBL] [Abstract][Full Text] [Related]
11. PCK3145 inhibits proliferation and induces apoptosis in breast and colon cancer cells.
Kostopoulos A; Papageorgiou E; Koutsilieris M; Sivolapenko G
Anticancer Res; 2015 Mar; 35(3):1377-84. PubMed ID: 25750288
[TBL] [Abstract][Full Text] [Related]
12. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
Wood JM
Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
[TBL] [Abstract][Full Text] [Related]
14. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
15. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
16. Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers.
Joseph IB; Isaacs JT
Cancer Res; 1997 Mar; 57(6):1054-7. PubMed ID: 9067270
[TBL] [Abstract][Full Text] [Related]
17. Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis.
Adya R; Tan BK; Punn A; Chen J; Randeva HS
Cardiovasc Res; 2008 May; 78(2):356-65. PubMed ID: 18093986
[TBL] [Abstract][Full Text] [Related]
18. Pyrazolo-pyrimidine-derived c-Src inhibitor reduces angiogenesis and survival of squamous carcinoma cells by suppressing vascular endothelial growth factor production and signaling.
Donnini S; Monti M; Castagnini C; Solito R; Botta M; Schenone S; Giachetti A; Ziche M
Int J Cancer; 2007 Mar; 120(5):995-1004. PubMed ID: 17131343
[TBL] [Abstract][Full Text] [Related]
19. A potential autocrine role for vascular endothelial growth factor in prostate cancer.
Jackson MW; Roberts JS; Heckford SE; Ricciardelli C; Stahl J; Choong C; Horsfall DJ; Tilley WD
Cancer Res; 2002 Feb; 62(3):854-9. PubMed ID: 11830543
[TBL] [Abstract][Full Text] [Related]
20. Cancer antineovascular therapy with liposome drug delivery systems targeted to BiP/GRP78.
Katanasaka Y; Ishii T; Asai T; Naitou H; Maeda N; Koizumi F; Miyagawa S; Ohashi N; Oku N
Int J Cancer; 2010 Dec; 127(11):2685-98. PubMed ID: 20178102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
